Tromethamine

Tromethamine

SCHEMBL2859906

CS(=O)(=O)C(F)(F)F.NC(CO)(CO)CO

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA

The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
KMT2A Q03164 1/20 0.50
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA13 Q8N1Q1 1/20 0.35
F2 P00734 2/20 0.31
PRSS1 P07477 2/20 0.31
PRSS2 P07478 2/20 0.31
PRSS3 P35030 2/20 0.31
ATR Q13535 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tromethamine SCHEMBL21647312 0.82 MEN1 (0.53) MEN1LMNAKMT2ACA1CA2
Tromethamine SCHEMBL11143695 0.81 MEN1 (0.59) MEN1LMNAKMT2ACA1CA2
Tromethamine SCHEMBL1508805 0.75 LMNA (0.67) MEN1LMNAKMT2ACA1CA2
Tromethamine SCHEMBL5988271 0.75 LMNA (0.67) MEN1LMNAKMT2ACA1CA2
Tromethamine SCHEMBL4939766 0.75 LMNA (0.67) MEN1LMNAKMT2ACA1CA2
SCHEMBL245997 0.74
SCHEMBL1863468 0.74
Tromethamine SCHEMBL6064575 0.74 LMNA (0.56) MEN1LMNAKMT2ACA1CA2
Tromethamine SCHEMBL7193959 0.71 MEN1 (0.83) MEN1LMNAKMT2A
Tromethamine SCHEMBL28216031 0.71 MEN1 (0.83) MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998351-B1 USE OF TRIS (TRIFLUORO METHYLSULFONYL) METHANE, IN ADDITION TO ALKALINE METAL SALTS AND ALKALINE-EARTH METAL SALTS THEREOF AS CATALYSTS DURING C-C BONDING SYNTHESES AND THE NOVEL Mg SALT OF TRIS (TRIFLUORO METHYLSULFONYL) METHANE MERCK PATENT GMBH (DE) 2001-05-30 EP claimed
EP-3374461-A1 BARRIER ADHESIVE MASS WITH POLYMER GETTER MATERIAL tesa SE (DE) 2018-09-19 EP disclosed
US-7713658-B2 Material for electrolytic solutions and use thereof NIPPON SHOKUBAI CO., LTD. (JP) 2010-05-11 US disclosed
US-7521006-B2 Diimmonium compound and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2009-04-21 US disclosed
US-20080067478-A1 Quaternary salt of N,N,N',N'-tetrakis(p-aminophenyl)phenylene diimmonium compound; stability; heat and light resistance; near-infrared aborbing filters, optical recording media and filters, plasma display panels NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2008-03-20 US disclosed
US-6433227-B1 REACTING ELECTROPHILIC AND NUCLEOPHILIC COMPOUND MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2002-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080067478-A1 Quaternary salt of N,N,N',N'-tetrakis(p-aminophenyl)phenylene diimmonium compound; stability; heat and light resistance; near-infrared aborbing filters, optical recording media and filters, plasma display panels ATP1B1, RER1, PNISR MEN1 1463/4885LMNA 1924/4885KMT2A 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.